• Share
  • Email
  • Print

Amy S. Wallace

Partner
+1.919.743.7326
Fax +1.919.516.2018
Amy Wallace practices in the areas of securities law, corporate law, and mergers and acquisitions. Her practice includes public offerings and private placements of securities, compliance with SEC and stock exchange reporting requirements, corporate governance matters, and corporate investigations. She primarily represents small and mid-cap companies across a range of industries, including life sciences, health care, consumer products, e-commerce, manufacturing, and technology. Ms. Wallace has also represented emerging growth companies in venture capital, private equity, and other general corporate matters.

Professional Background

Prior to joining the firm, Ms. Wallace served as a partner at a North Carolina-based law firm.

Achievements

  • Staff Member, North Carolina Law Review

Professional/Civic Activities

  • North Carolina Bar Association
  • Wake County Bar Association
  • Represented the largest electric utility in the United States in multiple registered debt offerings aggregating approximately $2.5 billion.
  • Represented a Nasdaq-listed molecular diagnostics company in its public offering of convertible senior notes for gross proceeds of approximately $750 million.
  • Represented the special committee of a publicly-traded bank holding company in connection with its $645 million acquisition of another bank holding company.
  • Represented a publicly-traded company and leading provider of end-to-end spend management solutions in its sale of the company to a leading technology-focused private equity firm for approximately $509 million.
  • Represented a Nasdaq-listed provider of specialized cardiovascular diagnostic laboratory tests in its sale of the company to an S&P 500 company for approximately $85 million.
  • Represented a venture capital firm in its secondary sale of $1.35 billion in portfolio company interests to a spin-out fund.
  • Represented a major convenience store chain in its Rule 144A/Regulation S issuance of $250 million in unsecured debt and subsequent registered exchange offer.
  • Represented a global pharmaceutical contract manufacturing and development company in its $30 million subscription rights offering in connection with an acquisition and refinancing.
  • Represented a publicly traded bank holding company in a rights offering and concurrent standby offering for aggregate gross proceeds of $24 million.
  • Represented the largest electric utility in the United States in issuer tender offer for over $60 million in contingent value obligations (CVOs).
  • Represented a Nasdaq-listed company in its issuer tender offer to exchange outstanding stock options and stock appreciation rights (SARs) for newly issued SARs.
  • Represented a large private company in its issuer tender offer for over $1 billion in common stock.
  • Represented a Nasdaq-listed bank holding company in a $180 million sale of a majority equity interest.
  • Represented a medical device company in its acquisition of another medical device company and concurrent $17 million PIPE transaction for common stock.
  • Represented a medical device company in its PIPE transaction for approximately $10 million aggregate principal amount of subordinated convertible debentures and warrants.
  • Represented a medical device company in its $7.3 million public equity line financing.
  • Represented a health care provider network in Regulation A Tier 2 offering in connection with a joint venture transaction.
  • Represented a real estate micro-lending crowdfunding platform in Regulation A Tier 1 and Tier 2 offerings.
  • Represented an international agricultural biotechnology company in its sale of the company to a global pharmaceutical company for approximately $155 million.
  • Represented public companies in going dark and going private transactions, both within and outside the acquisition context.
  • Represented a Nasdaq-listed company in listing and subsequent delisting from the SIX Swiss Exchange.
  • Assisted public companies with corporate investigations, both internally and in response to regulatory inquiries.